Danaher Corporation (DHR): Price and Financial Metrics

Danaher Corporation (DHR)

Today's Latest Price: $232.66 USD

1.32 (-0.56%)

Updated Oct 23 7:00pm

Add DHR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 60 in Industrial - Machinery

See all "A" rated Strong Buy stocks

DHR Stock Summary

  • Danaher Corp's market capitalization of $160,716,572,022 is ahead of 99.03% of US-listed equities.
  • DHR's went public 32.99 years ago, making it older than 90.66% of listed US stocks we're tracking.
  • Price to trailing twelve month operating cash flow for DHR is currently 37.02, higher than 89.83% of US stocks with positive operating cash flow.
  • Stocks that are quantitatively similar to DHR, based on their financial statements, market capitalization, and price volatility, are MDT, NVO, TMO, TMUS, and SAP.
  • Visit DHR's SEC page to see the company's official filings. To visit the company's web site, go to www.danaher.com.

DHR Stock Price Chart Interactive Chart >

Price chart for DHR

DHR Price/Volume Stats

Current price $232.66 52-week high $236.55
Prev. close $233.98 52-week low $119.60
Day low $231.33 Volume 2,268,967
Day high $236.55 Avg. volume 2,863,495
50-day MA $212.14 Dividend yield 0.31%
200-day MA $176.69 Market Cap 165.05B

Danaher Corporation (DHR) Company Bio

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company was founded in 1969 and is based in Washington, the District of Columbia.

DHR Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$232.66$50.1 -78%

Below please find a table outlining a discounted cash flow forecast for DHR, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Danaher Corp ranked in the 17th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Danaher Corp ended up being:

  • The company's debt burden, as measured by earnings divided by interest payments, is 23 -- which is good for besting 88.64% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • DHR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 32.5% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DHR, try TFX, ABC, ICUI, EHC, and ZBH.

DHR Latest News Stream

Event/Time News Detail
Loading, please wait...

DHR Latest Social Stream

Loading social stream, please wait...

View Full DHR Social Stream

Latest DHR News From Around the Web

Below are the latest news stories about Danaher Corp that investors may wish to consider to help them evaluate DHR as an investment opportunity.

Flow Cytometry Market in Austria Size to hit $27.7 million by 2020, Top Prominent Players: Danaher Corporation, Becton, Dickinson and Co.

UPDATE AVAILABLE ON-DEMAND According to the report by Allied Market Research, the Austria Flow Cytometry market is estimated to register a CAGR of 12.3% from 2015 to 2020. The research helps leading players and startups to devise new strategies based on

OpenPR | October 2, 2020

Danaher Demands A Price For Its Quality

Danaher's (DHR) share price has seen a considerable increase recently, doubling within the past two years. Particularly interesting is the performance during the corona pandemic. Following a brief pullback in March, the stock of Danaher has risen well above its level before the corona crash. The price of the stock...

Maximilian Dorn on Seeking Alpha | October 1, 2020

Immunohistochemistry Market To Witness Steady Growth With Danaher, Merck KGaA, Thermo Fisher Scientific, PerkinElmer, Abcam Plc, Agilent Technologies, Bio SB, Bio-Rad Laboratories, Cell Signalling Technology and F. Hoffmann-La Roche among others

A report by The Insight Partner's on the Immunohistochemistry Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the market

OpenPR | October 1, 2020

Repligen: A Niche Play On Biologics

Thesis Repligen (NASDAQ: RGEN) trades at a rather high valuation, but there are still very good reasons to buy the company today. Repligen supports the biologics industry, which has started a period of strong secular growth that should fuel growing cash flows and earnings over the next several years. This...

Star Investments on Seeking Alpha | September 30, 2020

Research Antibodies Market Exhibits a Lucrative Growth Potential during 2020-2025 | Global Key Company’s – BD, Thermo Fisher, Merck, Bio-Rad Lab, Roche, Agilent, Danaher, Lonza

Overview of Global Research Antibodies Market: The Research Antibodies Market has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Research Antibodies Market size to maintain the average annual growth rate of 6.15% from

OpenPR | September 30, 2020

Read More 'DHR' Stories Here

DHR Price Returns

1-mo 12.31%
3-mo 17.03%
6-mo 41.00%
1-year 72.00%
3-year 158.48%
5-year 161.26%
YTD 52.09%
2019 49.55%
2018 11.80%
2017 20.01%
2016 -15.65%
2015 9.04%

DHR Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full DHR Dividend History

Continue Researching DHR

Want to see what other sources are saying about Danaher Corp's financials and stock price? Try the links below:

Danaher Corp (DHR) Stock Price | Nasdaq
Danaher Corp (DHR) Stock Quote, History and News - Yahoo Finance
Danaher Corp (DHR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8669 seconds.